ENYO Pharma

Executive Summary

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, founded in 2014 with a mission to develop innovative treatments for patients with impaired kidney function. The company's lead asset, Vonafexor, is an oral FXR agonist with fibrolytic and anti-inflammatory properties, currently in Phase 2 clinical development targeting both kidney and liver diseases. By modulating FXR, Vonafexor aims to address underlying fibrosis and inflammation, offering potential therapeutic benefits beyond standard care. ENYO's pipeline is focused on high-unmet-need indications, including Alport syndrome and non-alcoholic steatohepatitis (NASH), positioning the company to capture significant market opportunities if clinical data prove positive. The company remains private, with a lean operation and a clear strategic focus on advancing Vonafexor through key value-inflection points.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for Vonafexor in Alport syndrome50% success
• Q4 2026Phase 2 data readout for Vonafexor in NASH45% success
• TBDPotential partnership or licensing deal for Vonafexor40% success